Share:
Peer-Reviewed Publication
Clin Exp Hypertens2026;48(1):2627352.December 31, 2026Journal Article

ANXA2, DBN1, ZNF385D, and IL6ST: Endothelial cell biomarkers linking atherosclerosis progression to immune microenvironment dysregulation.

Fenlong Xue1,2, Ying Shi3, Yuhui Zhang1,2, Rangfei Zhu4,5,6
1Department of Cardiovascular Surgery, Chest Hospital, Tianjin University, Tianjin, People's Republic of China.
2Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, People's Republic of China.
3Tianjin Institute of Cardiovascular Disease, Tianjin Chest Hospital, Tianjin, People's Republic of China.
4Cardio-Cerebral Vascular Disease Prevention and Treatment Innovation Center, Donghai County People's Hospital, Lianyungang, People's Republic of China.
5Jiangnan University Smart Healthcare Joint Laboratory, Donghai County People's Hospital, Lianyungang, People's Republic of China.
6ZUMRI - Donghai County People's Hospital Joint Lab, Lianyungang, People's Republic of China.

Abstract

BACKGROUND: Atherosclerosis (AS) is a complex cardiovascular disorder driven by endothelial cell dysfunction and immune microenvironment dysregulation. We identified novel endothelial-related diagnostic biomarkers through multi-omics integration and machine learning approaches. METHODS: Single‑cell atlas of AS was constructed from scRNA-seq data using the Seurat. Endothelial cell‑specific co‑expr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.